Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
The independent financial analyst theScreener just slightly lowered the general evaluation of KITE PHARMA INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title confirms its rating of 3 out of 4 stars while its market behaviour remains unchanged and can be qualified as defensive. However, a marginally less favourable environment forces theScreener to downgrade slightly the title, which now shows an overall rating of Slightly Positive. As of the analysis...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Kite Pharma, Inc. ("Kite Pharma" or the "Company") (NASDAQ: KITE) stock prior to August 28, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Kite Pharma, Inc. to Gilead Sciences, Inc. (NASDAQ: GILD). The transaction is valued at approximately $11.9 billion. Under the terms of the transaction, shareholders ...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Kite Pharma, Inc. ("Kite Pharma" or the "Company") (NASDAQ:KITE) stock prior to August 28, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Kite Pharma, Inc. to Gilead Sciences, Inc. (NASDAQ: GILD). The transaction is valued at approximately $11.9 billion. Under the terms of the transaction, shareholders o...
WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of Kite Pharma, Inc. (NASDAQ GS: KITE)? Did you purchase any of your shares prior to August 28, 2017? Do you think the proposed buyout is fair? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Kite Pharma, Inc. (“Kite Pharma” or the “Company”) (NASDAQ GS: KITE) regar...
Gilead will acquire Kite Pharma in an all-cash deal worth $11.9 billion ($180 per share), and we continue to view Gilead shares as slightly undervalued, with a fair value estimate of $84 per share. While this does diversify Gilead’s portfolio, the price that Gilead paid looks neutral to long-term ROICs, assuming approval and strong pricing for Kite’s cell therapy axicabtagene ciloleucel (axi-cel) in the biggest indications of second- and third-line DLBCL, and we think Gilead’s wide moat re...
Gilead will acquire Kite Pharma in an all-cash deal worth $11.9 billion ($180 per share), and we continue to view Gilead shares as slightly undervalued, with a fair value estimate of $84 per share. While this does diversify Gilead’s portfolio, the price that Gilead paid looks neutral to long-term ROICs, assuming approval and strong pricing for Kite’s cell therapy axicabtagene ciloleucel (axi-cel) in the biggest indications of second- and third-line DLBCL, and we think Gilead’s wide moat re...
NEW YORK--(BUSINESS WIRE)-- Rowley Law PLLC is investigating potential claims against Kite Pharma, Inc. (NASDAQ: KITE) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Gilead Sciences, Inc. for $180.00 per share in cash. The transaction is valued at approximately $11.9 billion and is expected to close in the fourth quarter of 2017. If you are a Kite Pharma, Inc. shareholder and are interested in obtaining additional information regarding this investigation, please ...
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE), a leading cell therapy company, today highlighted the publication of results in the Journal of Clinical Oncology from a National Cancer Institute (NCI) study evaluating the safety and efficacy of a MAGE A3 T cell receptor (TCR) engineered T-cell therapy. The cancer testis antigen MAGE A3 is frequently found in many cancers including bladder, esophageal, cervical, head and neck, lung, and ovarian cancers, among others. The research, led by Steven A. Rosenbe...
We believe it is highly likely Kite’s CAR-T therapy axi-cel will receive regulatory approval in the U.S. after learning the firm will not require a Food and Drug Administration advisory committee meeting. In July, the advisory committee unanimously voted in favor of Novartis’ CAR-T product, tisagenlecleucel (formerly CTL019), which paved the way for the novel therapeutic class. As a result, our fair value estimate for Kite increases to $102 per share from $84. We think it is still too early ...
News in Kite's first-quarter earnings call that a patient died in the CAR-T program caused shares to plummet over 10% on May 8. Based on the details released so far, the news does not change our underlying assumptions for Kite’s CAR-T therapy axi-cel, but we are increasing our fair value estimate to $84 per share from $82 to reflect our updated expectations for U.S. corporate tax reform effective 2018. We stand by our positive moat trend rating for the firm, which is supported by Kite’s lead...
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE), a leading cell therapy company, today reported second quarter 2017 financial results and provided a corporate update for the period ended June 30, 2017. "We’ve continued to make significant progress on key clinical and commercial milestones in the last six months alone," said Arie Belldegrun, M.D., FACS, Chairman, President, and Chief Executive Officer of Kite. “With the anticipated events on the horizon for the remainder of 2017, the potential for CAR-T...
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE), a leading cell therapy company, today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a Phase 1, first-in-human trial of KITE-585, a CAR-T cell therapy engineered to target B-cell maturation antigen (BCMA) in patients with relapsed/refractory multiple myeloma. “KITE-585 has the potential to become Kite’s next significant advance in cell therapy for patients with cancer...
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc., (Nasdaq:KITE), a leading cell therapy company, today announced that patients in the European Union (EU) are now being treated with its lead investigational candidate, axicabtagene ciloleucel, in the safety expansion cohort of ZUMA-1 (ClinicalTrials.gov, NCT: 02348216). Kite is currently enrolling adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), and transformed follicular lymphoma (TFL) at multipl...
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc., (Nasdaq:KITE), a leading cell therapy company, today highlighted the publication of the first large-scale multi-institutional analysis of outcomes of patients with refractory aggressive non-Hodgkin lymphoma (NHL) in the latest electronic edition of BLOOD. The study, SCHOLAR-1 (Retrospective Non-Hodgkin Lymphoma Research), showed outcomes in patients with refractory aggressive NHL subtypes including diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (...
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc., (Nasdaq:KITE), a leading cell therapy company, today announced that patients with relapsed/refractory indolent B-cell non-Hodgkin lymphoma (iNHL) are now being treated in its Phase 2 ZUMA-5 trial with its lead investigational candidate, axicabtagene ciloleucel (axi-cel). This study builds upon early clinical results using the same axi-cel anti-CD19 construct previously published in the March 2012 issue of Blood, “B-cell Depletion and Remissions of malignancy along with cytokin...
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE), a leading cell therapy company, today announced that management will present at the Canaccord Genuity 37th Annual Growth Conference on Wednesday, August 9, 2017 at 2:00 pm Eastern Time in Boston, MA. A live audio webcast of the event will be available on the Investors section of Kite's website, www.kitepharma.com. A replay of the webcast will be available on the website for approximately 30 days. About Kite Kite is a bioph...
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE), a leading cell therapy company, today announced that it will report second quarter 2017 financial results on Tuesday, August 8, 2017, prior to the open of U.S. based financial markets. The announcement will be followed by a live audio webcast and conference call at 8:30 AM ET / 5:30 AM PT. Audio Webcast The webcast will be made available on the Company's website at www.kitepharma.com under the Investors tab in the Events and Presentations sectio...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.